Waltham, United States
Naveris is a biotech company founded in 2017 and based in Waltham, Massachusetts. The company specializes in producing highly sensitive blood tests for cancer detection. These tests enable early diagnosis in asymptomatic individuals, real-time monitoring for patients undergoing treatment, and detection of cancer recurrence in patients in remission. Naveris employs proprietary 3D biomimetic technology that mimics the complex structure and signaling pathways of human tissues and tumors outside the body. This innovative approach allows researchers to efficiently establish patient-specific tumor models, facilitating advanced designs for oncology clinical trials and precision medicine to appropriately match therapies with patients.
The company recently received a significant $33.40M Series A investment on 19 September 2022. The investors in this round included BrightEdge Ventures, Gurnet Point Capital, and TechU Ventures. This investment reflects confidence in Naveris' innovative approach and its potential to make substantial contributions to cancer diagnosis and treatment advancements in the biotech and healthcare industries.
